^
    Back
    Association details:
    Biomarker:ATXN1L underexpression
    Cancer:Melanoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cell Rep
    Title:

    ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition

    Excerpt:
    Data from 30 BRAFV600-mutant melanoma metastases derived from 21 patients treated with dabrafenib or vemurafenib....This observation suggests that lower ATXN1L expression marks tumors with intrinsic resistance to BRAF or MEK inhibitor therapy in BRAF-mutant melanoma.
    DOI:
    10.1016/j.celrep.2017.01.031